Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

CONCLUSIONS: Combination of PGA appears to be safe and very active against platinum-resistant/refractory ovarian cancer and merits further evaluation prospectively. A randomized phase II study (NCTO 1936974) is currently under way to confirm this important finding. PMID: 29767862 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research